Shares of Atreca (NASDAQ:BCEL) have been given an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus price target of $25.50 for the company and are predicting that the company will post ($0.55) EPS for the current quarter, according to Zacks. Zacks has also given Atreca an industry rank of 99 out of 256 based on the ratings given to its competitors.
Several equities analysts have recently weighed in on BCEL shares. Canaccord Genuity started coverage on shares of Atreca in a report on Monday, July 15th. They set a “buy” rating and a $23.00 target price for the company. Evercore ISI initiated coverage on Atreca in a report on Monday, July 15th. They issued an “outperform” rating and a $16.63 price objective for the company. Stifel Nicolaus initiated coverage on Atreca in a report on Monday, July 15th. They issued a “buy” rating and a $28.00 price objective for the company. Finally, Cowen reissued a “buy” rating on shares of Atreca in a report on Wednesday.
Shares of NASDAQ:BCEL traded up $0.55 during trading on Friday, hitting $16.65. 162,577 shares of the stock traded hands, compared to its average volume of 87,149. The business’s fifty day simple moving average is $14.69. Atreca has a 52-week low of $10.29 and a 52-week high of $20.00.
Atreca (NASDAQ:BCEL) last posted its earnings results on Tuesday, August 13th. The company reported ($3.67) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($2.90). As a group, equities research analysts forecast that Atreca will post -3.08 EPS for the current year.
Atreca Company Profile
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Recommended Story: The role of implied volatility with call option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.